medigraphic.com

2024, Number 1

<< Back Next >>

Enf Infec Microbiol 2024; 44 (1)

Evolution of resistance of gramnegative bacilli in a tertiary hospital in Mexico: 2001-2020

Esparza AS, Garza GE, González DE, Pérez GHR, Morfín OR, Vázquez LM, Pérez SC, Heredia CJR, Zavala SML, Escobedo SR, Aguirre DSA, Garay SA, Pitones PMG, Rodríguez NE

Language: Spanish
References: 31
Page: 21-28
PDF size: 252.66 Kb.


ABSTRACT

Gram-negative bacteria are steadily evolving and developing antibiotic resistance. In this study, the resistance of gram-negative bacteria isolated during 2001-2020 in a tertiary care hospital in Mexico was studied. Routine drug resistance results for Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp. isolates from clinical specimens over twenty years were analyzed. The isolates with intermediate susceptibility were grouped with resistant ones, forming a non-susceptible group (NS). All results were analyzed using the WHONET 5.6 software. Results were stratified into four five-year periods and compared. A total of 61 691 unique isolates were recorded, of which 28 518 were E. coli isolates, 9 629 K. pneumoniae, 9 124 A. baumannii, 10 031 P. aeruginosa, and 4 389 Enterobacter spp. There was a significant increase in the resistance of NS K. pneumoniae to most antibiotics. In contrast, there was a decrease in the non-susceptibility of P. aeruginosa and Enterobacter spp. to most antibiotics. Furthermore, there was an increase in the NS of A. baumannii to cefepime and meropenem during 2010-2020. Lastly, the NS of E. coli constantly increased for third generation cephalosporins, and ciprofloxacin. Gram-negative bacilli resistance is increasing for some antibiotics in a third-level hospital in Mexico. The need for continuous monitoring of antibiotic resistance is crucial.


REFERENCES

  1. Rice, L.B., “Federal funding for the study of antimicrobialresistance in nosocomial pathogens: no eskape”, JInfect Dis, 2008, 197: 1079-1081. doi: 10.1086/533452.Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/18419525.

  2. Boucher, H.W., Talbot, G.H., Bradley, J.S., Edwards, J.E.,Gilbert, D., Rice, L.B., Scheld, M., Spellberg, B. y Bartlett,J., “Bad bugs, no drugs: no eskape! An update fromthe infectious diseases society of America”, Clin InfectDis, 2009, 48: 1-12. doi: 10.1086/595011. Disponible en:https://www.ncbi.nlm.nih.gov/pubmed/19035777.

  3. De Angelis, G., Fiori, B., Menchinelli, G., D’Inzeo, T.,Liotti, F.M., Morandotti, G.A., Sanguinetti, M., PosteraroB. y Spanu, T., “Incidence and antimicrobial resistancetrends in bloodstream infections caused by eskape andEscherichia coli at a large teaching hospital in Rome, a9-year analysis (2007-2015)”, Eur J Clin Microbiol InfectDis, 2018, 37: 1627-1636. doi: 10.1007/s10096-018-3292-9. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/29948360.

  4. Kadri, S.S., Adjemian, J., Lai, Y.L., Spaulding, A. B., Ricotta,E., Prevots, D.R., Palmore, T.N., Rhee, C., Klompas, M.,Dekker, J.P. et al., “Difficult-to-treat resistance in gram-negativebacteremia at 173 US hospitals: retrospective cohortanalysis of prevalence, predictors, and outcome ofresistance to all first-line agents”, Clin Infect Dis, 2018,67: 1803-1814. doi: 10.1093/cid/ciy378. Disponible en:https://www.ncbi.nlm.nih.gov/pubmed/30052813.

  5. Allegranzi, B., Bagheri Nejad, S., Combescure, C.,Graafmans, W., Attar, H., Donaldson, L. y Pittet, D,“Burden of endemic health-care-associated infectionin developing countries: systematic review and meta-analysis”, Lancet, 2011, 377: 228-241. doi: 10.1016/S0140-6736(10)61458-4. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/21146207.

  6. Ayobami, O., Brinkwirth, S., Eckmanns, T. y Markwart, R.,“Antibiotic resistance in hospital-acquired eskape-e infectionsin low- and lower-middle-income countries: a systematicreview and meta-analysis”, Emerg Microbes Infect,2022, 11: 443-451. doi: 10.1080/22221751.2022.2030196.Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/35034585.

  7. Tacconelli, E., Carrara, E., Savoldi, A., Harbarth, S.,Mendelson, M., Monnet, D.L., Pulcini, C., Kahlmeter, G.,Kluytmans, J., Carmeli, Y. et al., “Discovery, research,and development of new antibiotics: the who priority listof antibiotic-resistant bacteria and tuberculosis”, LancetInfect Dis, 2018, 18: 318-327. doi: 10.1016/S1473-3099(17)30753-3. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/29276051.

  8. Mancuso, G., Midiri, A., Gerace E. y Biondo, C., “Bacterialantibiotic resistance: the most critical pathogens”,Pathogens, 2021, 10: doi: 10.3390/pathogens10101310.Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/34684258.

  9. Collaborators gbdar, “Global mortality associated with33 bacterial pathogens in 2019: a systematic analysis forthe global burden of disease study 2019”, Lancet, 2023,400: 2221-2248. doi: 10.1016/S0140-6736(22)02185-7. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/36423648.

  10. European Antimicrobial Resistance, “The burden ofbacterial antimicrobial resistance in the who Europeanregion in 2019: a cross-country systematic analysis”,Lancet Public Health, 2022, 7: e897-e913. doi: 10.1016/S2468-2667(22)00225-0. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/36244350.

  11. Rodríguez Noriega, E., Morfin Otero, R. y Esparza Ahumada,S., “Beta-lactamase production and the patternsof bacterial resistance, 1988-1991”, Gac Med Mex,1994, 130: 355-360. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/7607365.

  12. Morfin-Otero, R., Tinoco-Favila, J.C., Sader, H.S., Salcido-Gutiérrez, L., Pérez-Gómez, H.R., González-Díaz, E.,Petersen, L. y Rodríguez-Noriega, E., “Resistance trendsin gram-negative bacteria: surveillance results from twomexican hospitals, 2005-2010”, bmc Res Notes, 2012,5: 277. doi: 10.1186/1756-0500-5-277. Disponible en:https://www.ncbi.nlm.nih.gov/pubmed/22676813.

  13. Morfin-Otero, R., Alcantar-Curiel, M.D., Rocha, M.J.,Alpuche-Aranda, C.M., Santos-Preciado, J.I., Gayosso-Vázquez, C., Araiza-Navarro, J.R., Flores-Vaca, M.,Esparza-Ahumada, S., González-Díaz, E. et al., “Acinetobacterbaumannii infections in a tertiary care hospitalin Mexico over the past 13 years”, Chemotherapy, 2013,59: 57-65. doi: 10.1159/000351098. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/23839011.

  14. Temkin, E., Fallach, N., Almagor, J., Gladstone, B.P.,Tacconelli, E., Carmeli, Y. y Consortium, D.-A., “Estimatingthe number of infections caused by antibiotic-resistantEscherichia coli and Klebsiella pneumoniae in2014: a modelling study”, Lancet Glob Health, 2018,6: e969-e979. doi: 10.1016/S2214-109X(18)30278-X.Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/30103998.

  15. Begier, E., Rosenthal, N.A., Gurtman, A., Kartashov, A.,Donald R.G.K. y Lockhart, S.P., “Epidemiology of invasiveEscherichia coli infection and antibiotic resistancestatus among patients treated in us hospitals: 2009-2016, Clin Infect Dis, 2021, 73: 565-574. doi: 10.1093/cid/ciab005. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/33420788.

  16. López-Jácome, L.E., Fernández-Rodríguez, D., Franco-Cendejas, R., Camacho-Ortiz, A., Morfin-Otero,M.D.R., Rodríguez-Noriega, E., Ponce-de-León, A.,Ortiz-Brizuela, E., Rojas-Larios, F., Velázquez-Acosta,M.D.C. et al., “Increment antimicrobial resistance duringthe covid-19 pandemic: results from the invifarnetwork”, Microb Drug Resist, 2022, 28: 338-345. doi:10.1089/mdr.2021.0231. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/34870473.

  17. Morfín-Otero, R., Mendoza-Olazaran, S., Silva-Sánchez,J., Rodríguez-Noriega, E., Laca-Díaz, J., Tinoco-Carrillo,P., Petersen, L., López, P., Reyna-Flores, F., Alcantar-Curiel,D. et al., “Characterization of Enterobacteriaceaeisolates obtained from a tertiary care hospital in Mexico,which produces extended-spectrum beta-lactamase”,Microb Drug Resist, 2013, 19: 378-383. doi: 10.1089/mdr.2012.0263. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/23725513.

  18. Garza-González, E., Franco-Cendejas, R., Morfín-Otero,R., Echaniz-Avilés, G., Rojas-Larios, F., Bocanegra-Ibarias, P., Flores-Trevino, S., Ponce-de-León, A.,Rodríguez-Noriega, E., Alavez-Ramírez N. et al., “Theevolution of antimicrobial resistance in Mexico duringthe last decade: results from the invifar group”, MicrobDrug Resist, 2020, 26: 1372-1382. doi: 10.1089/mdr.2019.0354. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/32027229.

  19. Loyola-Cruz, M.A., Durán-Manuel, E.M., Cruz-Cruz, C.,Márquez-Valdelamar, L.M., Bravata-Alcántara, J.C., Cortés-Ortiz, I.A., Cureno-Díaz, M.A., Ibáñez-Cervantes, G.,Fernández-Sánchez, V., Castro-Escarpulli, G. et al., “Eskapebacteria characterization reveals the presence ofAcinetobacter baumannii and Pseudomonas aeruginosaoutbreaks in covid-19/vap patients”, Am J Infect Control,

  20. 2022. doi: 10.1016/j.ajic.2022.08.012. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/36002081.20. Velázquez-Acosta, C., Cornejo-Juárez, P. y Volkow-Fernández,P., “Cepas e-eskape multidrogorresistentesaisladas en hemocultivos de pacientes con cancer”, SaludPública Mex, 2018, 60: 151-57. doi: 10.21149/8767.Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/29738654.

  21. De la Cruz-Hernández, I., Cornejo-Juárez, P., Téllez-Miranda,O., Barrera-Pérez, L., Sandoval-Hernández, S.,Vilar-Compte, D., Velázquez-Acosta C. y Volkow, P., “Microbiologyand prevalence of eskape-resistant strainsin catheter-related bloodstream infections in patientswith cancer”, Am J Infect Control, 2020, 48: 40-45. doi:10.1016/j.ajic.2019.06.008. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/31395288.

  22. Garza-González, E., Morfín-Otero, R., Mendoza-Olazaran,S., Bocanegra-Ibarias, P., Flores-Trevino, S., Rodríguez-Noriega, E., Ponce-de-León, A., Sánchez-Francia,D., Franco-Cendejas, R., Arroyo-Escalante, S. et al., “Asnapshot of antimicrobial resistance in Mexico. Resultsfrom 47 centers from 20 states during a six-month period”,plos One, 2019, 14: doi: e0209865. 10.1371/journal.pone.0209865. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/30913243.

  23. Garza-González, E., Bocanegra-Ibarias, P., Bobadilla-Del-Valle, M., Ponce-de-León-Garduño L.A., Esteban-Kenel, V., Silva-Sánchez J., Garza-Ramos, U.,Barrios-Camacho, H., López-Jacome, L.E., Colín-Castro,C.A. et al., “Drug resistance phenotypes and genotypesin Mexico in representative gram-negative species: resultsfrom the infivar network”, plos One, 2021, 16: doi:e0248614. 10.1371/journal.pone.0248614. Disponibleen: https://www.ncbi.nlm.nih.gov/pubmed/33730101.

  24. Bonten, M., Johnson, J.R., Van den Biggelaar, A.H.J.,Georgalis, L., Geurtsen, J., De Palacios, P.I., Gravenstein,S., Verstraeten, T., Hermans, P. y Poolman, J.T., “Epidemiologyof Escherichia coli bacteremia: a systematic literaturereview”, Clin Infect Dis, 2021, 72: 1211-19. doi:10.1093/cid/ciaa210. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/32406495.

  25. Feldman, S.F., Temkin, E., Wullfhart, L., Nutman, A.,Schechner, V., Shitrit, P., Shvartz, R., Schwaber, M.J., Andremont,A. y Carmeli, Y., “A nationwide population-basedstudy of Escherichia coli bloodstream infections:incidence, antimicrobial resistance and mortality”, ClinMicrobiol Infect, 2022, 28: 879 e1-79. doi: 10.1016/j.cmi.2021.12.009. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/34922002.

  26. Rudd, K.E., Johnson, S.C., Agesa, K.M., Shackelford, K.A.,Tsoi, D., Kievlan, D.R., Colombara, D.V., Ikuta, K.S., Kissoon,N., Finfer, S. et al., “Global, regional, and national sepsisincidence and mortality, 1990-2017: analysis for the globalburden of disease study”, Lancet, 2020, 395: 200-211. doi:10.1016/S0140-6736(19)32989-7. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/31954465.

  27. Girometti, N., Lewis, R.E., Giannella, M., Ambretti, S., Bartoletti,M., Tedeschi, S., Tumietto, F., Cristini, F., Trapani,F., Gaibani, P. et al., “Klebsiella pneumoniae bloodstreaminfection: epidemiology and impact of inappropriateempirical therapy”, Medicine (Baltimore), 2014, 93: 298-309. doi: 10.1097/MD.0000000000000111. Disponibleen: https://www.ncbi.nlm.nih.gov/pubmed/25398065.

  28. Gómez-Simmonds, A., Greenman, M., Sullivan, S.B.,Tanner, J.P., Sowash, M.G., Whittier, S. y Uhlemann,A.C., “Population structure of Klebsiella pneumoniaecausing bloodstream infections at a New York citytertiary care hospital: diversification of multidrug-resistantisolates”, J Clin Microbiol, 2015, 53: 2060-7. doi:10.1128/JCM.03455-14. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/25878348.

  29. Guarascio, A.J., Brickett, L.M., Porter, T.J., Lee, N.D.,Gorse E.E. y Covvey, J.R., “Development of a statewideantibiogram to assess regional trends in antibiotic-resistanteskape organisms”, J Pharm Pract, 2019, 32:19-27. doi: 10.1177/0897190017735425. Disponible en:https://www.ncbi.nlm.nih.gov/pubmed/29017424.

  30. Marturano, J.E. y Lowery, T.J., “Eskape pathogens inbloodstream infections are associated with highercost and mortality but can be predicted using diagnosesupon admission”, Open Forum Infect Dis, 2019, 6:ofz503. doi: 10.1093/ofid/ofz503. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/31844639.

  31. Pop-Vicas, A.E. y D’Agata, E.M., “The rising influx ofmultidrug-resistant gram-negative bacilli into a tertiarycare hospital”, Clin Infect Dis, 2005, 40: 1792-1798. doi:10.1086/430314. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/15909268.




2020     |     www.medigraphic.com